Korean J Obes 2012; 21(4): 197-202
Published online December 30, 2012
Copyright © Korean Society for the Study of Obesity.
Kyung Soo Kim, Seok Won Park*
Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Obesity is associated with a substantial increase in metabolic disorders and various cancers. As weight loss achieved with lifestyle intervention is modest, there is a need for drug treatment. Orlistat, phentermine, diethylpropion, phendimetrazine, mazindol have been approved as anti-obesity drugs by Korea Food and Drug Administration. Among these drugs, orlistat is the only approved drug for long-term weight management.
The U.S. Food and Drug Administration approved lorcaserin for treatment of obesity in June 2012. Qsymia is a combination of phentermine and topiramate that was approved by USFDA in July 2012. There are currently a large number of drugs for the treatment of obesity undergoing research and development. Drug therapy may play an important role in the treatment of obesity.
Keywords: Obesity, Drug therapy